Literature DB >> 36059037

Soluble factors in malignant ascites promote the metastatic adhesion of gastric adenocarcinoma cells.

Luai Al-Marzouki1,2, Vivian S Stavrakos1,2, Sanjima Pal1, Betty Giannias1, France Bourdeau1, Roni Rayes1, Nicholas Bertos1, Sara Najmeh1,2,3, Jonathan D Spicer1,2,3, Jonathan Cools-Lartigue1,2,3, Swneke D Bailey1,2, Lorenzo Ferri4,5,6, Veena Sangwan7,8.   

Abstract

BACKGROUND: Adenocarcinoma of the proximal stomach is the fastest rising malignancy in North America. It is commonly associated with peritoneal accumulation of malignant ascites (MA), a fluid containing cancer and inflammatory cells and soluble proteins. Peritoneal metastasis (PM) is the most common site of gastric cancer (GC) progression after curative-intent surgery and is the leading cause of death among GC patients. METHODS/
RESULTS: Using a panel of gastric adenocarcinoma cell lines (human: MKN 45, SNU-5; murine: NCC-S1M), we demonstrate that prior incubation of GC cells with MA results in a significant (> 1.7-fold) increase in the number of cells capable of adhering to human peritoneal mesothelial cells (HPMC) (p < 0.05). We then corroborate these findings using an ex vivo PM model and show that MA also significantly enhances the ability of GC cells to adhere to strips of human peritoneum (p < 0.05). Using a multiplex ELISA, we identify MIF and VEGF as consistently elevated across MA samples from GC patients (p < 0.05). We demonstrate that agents that block the effects of MIF or VEGF abrogate the ability of MA to stimulate the adhesion of GC cells to adhere to human peritoneum and promote both ex vivo and in vivo metastases.
CONCLUSION: Agents targeting MIF or VEGF may be relevant to the treatment or prevention of PM in GC patients.
© 2022. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.

Entities:  

Keywords:  Gastric cancer; Macrophage migration inhibitory factor (MIF); Malignant ascites; Peritoneal metastasis; Vascular endothelial growth factor (VEGF)

Year:  2022        PMID: 36059037     DOI: 10.1007/s10120-022-01338-1

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.701


  58 in total

1.  Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis.

Authors:  Gaya Spolverato; Aslam Ejaz; Yuhree Kim; Malcolm H Squires; George A Poultsides; Ryan C Fields; Carl Schmidt; Sharon M Weber; Konstantinos Votanopoulos; Shishir K Maithel; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2014-06-26       Impact factor: 6.113

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

3.  Patterns of gastric cancer metastasis in the United States.

Authors:  Joseph Sirody; Amy H Kaji; Daielle M Hari; Kathryn T Chen
Journal:  Am J Surg       Date:  2022-01-26       Impact factor: 3.125

4.  A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases.

Authors:  Willemieke P M Dijksterhuis; Tiuri E Kroese; Rob H A Verhoeven; Peter S N van Rossum; Stella Mook; Nadia Haj Mohammad; Maarten C C M Hulshof; Suzanne S Gisbertz; Jelle P Ruurda; Martijn G H van Oijen; Richard van Hillegersberg; Hanneke W M van Laarhoven
Journal:  Eur J Surg Oncol       Date:  2022-03-18       Impact factor: 4.037

5.  Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy.

Authors:  Yosuke Kano; Manabu Ohashi; Yusuke Muneoka; Daisuke Takahari; Keisho Chin; Kensei Yamaguchi; Satoshi Ida; Koshi Kumagai; Rie Makuuchi; Takeshi Sano; Souya Nunobe
Journal:  Eur J Surg Oncol       Date:  2021-04-21       Impact factor: 4.424

6.  Characteristics of gastric cancer recurrence five or more years after curative gastrectomy.

Authors:  Chang-Hyun Shin; Woo-Yong Lee; Seung-Woo Hong; Yeo-Goo Chang
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087

7.  Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy.

Authors:  Jing Xu; Li Shen; Yongjie Shui; Wei Yu; Qingqu Guo; Risheng Yu; Yulian Wu; Qichun Wei
Journal:  Cancer Med       Date:  2020-05-18       Impact factor: 4.452

Review 8.  Regional but fatal: Intraperitoneal metastasis in gastric cancer.

Authors:  Jia Wei; Nan-Die Wu; Bao-Rui Liu
Journal:  World J Gastroenterol       Date:  2016-09-07       Impact factor: 5.742

9.  Metastatic spread in patients with gastric cancer.

Authors:  Matias Riihimäki; Akseli Hemminki; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  Oncotarget       Date:  2016-08-09

10.  Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis: A protocol for systematic review and meta-analysis of randomized controlled trials.

Authors:  Yidan Lu; Zheng Jin; Song Zheng; Yurong Bai; Yangcheng Sun
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.